The current state of immunotherapy for gliomas: an eye toward the future.

Published

Journal Article (Review)

The last decade has seen a crescendo of FDA approvals for immunotherapies against solid tumors, yet glioblastoma remains a prominent holdout. Despite more than 4 decades of work with a wide range of immunotherapeutic modalities targeting glioblastoma, efficacy has been challenging to obtain. Earlier forms of immune-based platforms have now given way to more current approaches, including chimeric antigen receptor T-cells, personalized neoantigen vaccines, oncolytic viruses, and checkpoint blockade. The recent experiences with each, as well as the latest developments and anticipated challenges, are reviewed.

Full Text

Duke Authors

Cited Authors

  • Fecci, PE; Sampson, JH

Published Date

  • September 1, 2019

Published In

Volume / Issue

  • 131 / 3

Start / End Page

  • 657 - 666

PubMed ID

  • 31473668

Pubmed Central ID

  • 31473668

Electronic International Standard Serial Number (EISSN)

  • 1933-0693

Digital Object Identifier (DOI)

  • 10.3171/2019.5.JNS181762

Language

  • eng

Conference Location

  • United States